Analyst Price Targets — GLUE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 30, 2026 11:16 am | — | Guggenheim | $35.00 | $23.90 | StreetInsider | Monte Rosa Therapeutics (GLUE) PT Raised to $35 at GuggenheimMember Login |
| January 14, 2026 11:48 am | — | Piper Sandler | $37.00 | $23.99 | TheFly | Monte Rosa Therapeutics price target raised to $37 from $27.50 at Piper Sandler |
| January 7, 2026 7:27 pm | — | Jefferies | $31.00 | $23.29 | TheFly | Monte Rosa Therapeutics price target raised to $31 from $22 at Jefferies |
| January 7, 2026 3:05 pm | — | Wedbush | $37.00 | $24.31 | TheFly | Monte Rosa Therapeutics price target raised to $37 from $26 at Wedbush |
| December 17, 2025 9:28 am | Kelly Shi | Jefferies | $22.00 | $18.66 | StreetInsider | Monte Rosa Therapeutics (GLUE) PT Raised to $22 at Jefferies |
| December 16, 2025 10:24 am | — | Wells Fargo | $22.00 | $16.45 | TheFly | Monte Rosa Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo |
Latest News for GLUE
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of inducement equity awards to three newly hired non-executive employees as a material inducement to commencing their employment with the Company. The employees received, in the aggregate, non-qualified…
This clinical-stage biotech focused on precision medicines reported a notable insider sale amid a year of exceptional share price gains.
Monte Rosa Therapeutics, Inc. is a leading biotech in molecular glue degraders, with a $1.45bn valuation and robust partnerships with Novartis and Roche. GLUE's pipeline shows promising Phase 1 data, especially for MRT-8102 and MRT-6160, but lacks Phase 2 proof-of-concept results to fully derisk programs. Significant cash runway ($675m) and milestone-rich deals provide operational security while awaiting pivotal…
BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of inducement equity awards to four newly hired non-executive employees as a material inducement to commencing their employment with the Company. The employees received, in the aggregate, non-qualified…
BOSTON, May 20, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: TD Cowen 7th Annual Oncology Innovation Summit (virtual) – fireside chat, May 27, 2026, at 12:00 p.m. ET Jefferies Global Healthcare…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for GLUE.
U.S. House Trading
No House trades found for GLUE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.